Helgstrand U
Scand J Gastroenterol Suppl. 1986;121:40-5. doi: 10.3109/00365528609091677.
The mucosal fibrinolytic activity was estimated in 24 patients with duodenal ulcer and in 11 patients with gastric ulcer. The fibrinolytic activity was estimated in biopsy specimens taken during gastroscopy. Specimens were taken in the corpus, in the antrum, and in the duodenal mucosa. In patients with duodenal ulcer the fibrinolytic activity was significantly higher in the corpus and antrum mucosa, whereas no difference was observed in the duodenal mucosa compared with controls. Gastric ulcer patients had, compared with controls, significantly higher activity in the corpus mucosa only. Fourteen patients with duodenal ulcer and five with gastric ulcer were treated with 1 g cimetidine daily for 4 weeks. The mucosal fibrinolytic activity was estimated before and after treatment in the above-mentioned regions. A significant reduction was observed after treatment in patients with duodenal ulcer, both in the corpus and in the duodenal mucosa, whereas no difference was seen in the duodenum. In patients with gastric ulcer a reduction was observed in the corpus mucosa only. The fibrinolytic activity estimated was plasminogen activator, and not other proteases, in all estimations.
对24例十二指肠溃疡患者和11例胃溃疡患者的黏膜纤溶活性进行了评估。纤溶活性是在胃镜检查时获取的活检标本中进行评估的。标本取自胃体、胃窦和十二指肠黏膜。十二指肠溃疡患者的胃体和胃窦黏膜纤溶活性显著高于对照组,而十二指肠黏膜与对照组相比无差异。胃溃疡患者与对照组相比,仅胃体黏膜活性显著更高。14例十二指肠溃疡患者和5例胃溃疡患者每天服用1克西咪替丁,持续4周。在上述区域治疗前后评估黏膜纤溶活性。十二指肠溃疡患者治疗后,胃体和十二指肠黏膜的纤溶活性均显著降低,而十二指肠未见差异。胃溃疡患者仅胃体黏膜纤溶活性降低。在所有评估中,所测定的纤溶活性是纤溶酶原激活物,而非其他蛋白酶。